Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2006

01.06.2006

Expression of Interleukin 11 and Its Receptor and Their Prognostic Value in Human Breast Cancer

verfasst von: Satheesha Hanavadi, MS, FRCS, Tracey A. Martin, PhD, Gareth Watkins, HND, Robert E. Mansel, MS, FRCS, Wen G. Jiang, MB MCh, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

Recent experimental evidence has shown a potential role of interleukin (IL)-11 and its receptor in breast cancer development and progression. However, there is little clinical information to support this hypothesis. We examined the expression of IL-11 and its receptor in primary breast cancer tissue samples and correlated their level of expression with the clinical outcome.

Methods

Primary breast cancer samples (n = 109) and matched background tissue obtained from patients in the cohort (n = 33) were processed for frozen section and RNA extraction. Frozen sections from matched tissues were immunostained with IL-11 and IL-11 receptor antibodies. Staining intensity was analyzed by computer image analysis. RNA was reverse-transcribed and quantified before analysis by quantitative polymerase chain reaction. Results were expressed as the number of transcripts (standardized by β-actin). The data were compared with the clinical outcome of the disease.

Results

The intensity of staining for both IL-11 and the IL-11 receptor was distinctly high in tumor samples (P < .01). The transcript level of IL-11 was significantly higher in node-positive tumor samples compared with node-negative samples (P = .02). Tumors with a poor prognostic index and poor histological grade showed a higher level of IL-11. A higher level of IL-11 was linked to poorer survival with Kaplan-Meier survival analysis.

Conclusions

IL-11 can be a predictor of poor prognosis in human breast cancer.
Literatur
1.
Zurück zum Zitat Pisani P, Parkin DM, Ferlay J. Estimates of worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55:891–903PubMed Pisani P, Parkin DM, Ferlay J. Estimates of worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55:891–903PubMed
2.
Zurück zum Zitat Van ‘t Veer LJ, Dai H, Van De Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530–6CrossRefPubMed Van ‘t Veer LJ, Dai H, Van De Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530–6CrossRefPubMed
3.
Zurück zum Zitat Kang Y, Seigel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3:537–49CrossRefPubMed Kang Y, Seigel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3:537–49CrossRefPubMed
4.
Zurück zum Zitat Crichton MB, Nichols JE, Zhao Y, Bulun SE, Simpson ER. Expression of transcript of interleukin-6 and related cytokines by human breast tumours, breast cancer cells and adipose stromal cells. Mol Cell Endocrinol 1996; 118:215–20CrossRefPubMed Crichton MB, Nichols JE, Zhao Y, Bulun SE, Simpson ER. Expression of transcript of interleukin-6 and related cytokines by human breast tumours, breast cancer cells and adipose stromal cells. Mol Cell Endocrinol 1996; 118:215–20CrossRefPubMed
5.
Zurück zum Zitat Douglas AM, Goss GA, Sutherland RL, et al. Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene 1997; 14:661–9CrossRefPubMed Douglas AM, Goss GA, Sutherland RL, et al. Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene 1997; 14:661–9CrossRefPubMed
6.
Zurück zum Zitat Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T. Suppression of interleukin-11 mediated bone resorption by cyclooxygenase inhibitor. J Cell Physiol 1998; 175:247–54CrossRefPubMed Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T. Suppression of interleukin-11 mediated bone resorption by cyclooxygenase inhibitor. J Cell Physiol 1998; 175:247–54CrossRefPubMed
7.
Zurück zum Zitat Lacroix M, Siwek B, Marie PJ, Body JJ. Production and regulation of interleukin-11 by breast cancer cells. Cancer Lett 1998; 127:29–35CrossRefPubMed Lacroix M, Siwek B, Marie PJ, Body JJ. Production and regulation of interleukin-11 by breast cancer cells. Cancer Lett 1998; 127:29–35CrossRefPubMed
8.
Zurück zum Zitat Manolagas SC, Jilka RL. Bone marrow, cytokines and remodelling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332:305–11CrossRefPubMed Manolagas SC, Jilka RL. Bone marrow, cytokines and remodelling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332:305–11CrossRefPubMed
10.
Zurück zum Zitat Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48:6876–81PubMed Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48:6876–81PubMed
11.
Zurück zum Zitat Morgan H, Tumber A, Hill PA. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and down regulating granulocyte/macrophage colony-stimulating factor. Int J Cancer 2004; 109:653–60CrossRefPubMed Morgan H, Tumber A, Hill PA. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and down regulating granulocyte/macrophage colony-stimulating factor. Int J Cancer 2004; 109:653–60CrossRefPubMed
12.
Zurück zum Zitat Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992; 22:207–19CrossRefPubMed Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992; 22:207–19CrossRefPubMed
13.
Zurück zum Zitat Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403–10PubMed Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403–10PubMed
14.
Zurück zum Zitat Chomczynske P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156–9 Chomczynske P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156–9
15.
Zurück zum Zitat Jiang WG, Watkins G, Lane J, et al. Prognostic value of Rho family and rho-GDIs in breast cancer. Clin Cancer Res 2003; 9:6432–40PubMed Jiang WG, Watkins G, Lane J, et al. Prognostic value of Rho family and rho-GDIs in breast cancer. Clin Cancer Res 2003; 9:6432–40PubMed
16.
Zurück zum Zitat Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005; 12:1–9CrossRef Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005; 12:1–9CrossRef
17.
Zurück zum Zitat Davies G, Jiang WG, Mason MD. Cell–cell adhesion and signaling intermediates in human prostate cancer. J Urol 2000; 163:985–92CrossRefPubMed Davies G, Jiang WG, Mason MD. Cell–cell adhesion and signaling intermediates in human prostate cancer. J Urol 2000; 163:985–92CrossRefPubMed
18.
Zurück zum Zitat King JAC, Ofori-Acquash AF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG. Prognostic value of ALCAM in human breast cancer. Breast Cancer Res 2004; 6:478–87CrossRef King JAC, Ofori-Acquash AF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG. Prognostic value of ALCAM in human breast cancer. Breast Cancer Res 2004; 6:478–87CrossRef
19.
Zurück zum Zitat Paul SR, Bennett F, Calvotti JA, et al. Molecular cloning of a cDNA encoding interleukin-11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 1990; 87:7512–6PubMed Paul SR, Bennett F, Calvotti JA, et al. Molecular cloning of a cDNA encoding interleukin-11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 1990; 87:7512–6PubMed
20.
Zurück zum Zitat Du X, Williams DA. Interleukin-11: review of molecular, cell biology and clinical use. Blood 1997; 89:3897–908PubMed Du X, Williams DA. Interleukin-11: review of molecular, cell biology and clinical use. Blood 1997; 89:3897–908PubMed
21.
Zurück zum Zitat Sotiriou C, Lacroix M, Lespagnard L, Larsimont D, Paesmans M, Body JJ. Interleukin-6 and -11 expression in primary breast cancer and subsequent development of bone metastasis. Cancer Lett 2001; 169:87–95CrossRefPubMed Sotiriou C, Lacroix M, Lespagnard L, Larsimont D, Paesmans M, Body JJ. Interleukin-6 and -11 expression in primary breast cancer and subsequent development of bone metastasis. Cancer Lett 2001; 169:87–95CrossRefPubMed
Metadaten
Titel
Expression of Interleukin 11 and Its Receptor and Their Prognostic Value in Human Breast Cancer
verfasst von
Satheesha Hanavadi, MS, FRCS
Tracey A. Martin, PhD
Gareth Watkins, HND
Robert E. Mansel, MS, FRCS
Wen G. Jiang, MB MCh, MD
Publikationsdatum
01.06.2006
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2006
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2006.05.028

Weitere Artikel der Ausgabe 6/2006

Annals of Surgical Oncology 6/2006 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.